# Reduced Cortical Pyramidal Neuron Membrane Excitability and Synaptic Function in Parkinsonian Mice and Their Restoration by L-Dopa Treatment: Indirect Mediation by Striatal Dopaminergic Activity

## TL;DR

This study shows that dopamine loss in the striatum, not the cortex, affects brain function in Parkinson's disease, and restoring dopamine helps.

## Contribution

The study reveals that striatal dopamine indirectly controls cortical neuron activity, challenging previous assumptions about dopamine's role in the cortex.

## Key findings

- DA-depleted mice show reduced cortical pyramidal neuron excitability and synaptic function.
- L-dopa treatment reverses these deficits, but direct cortical dopamine has little effect.
- Striatal dopamine loss indirectly impacts cortical neurons, suggesting functional, not structural, changes.

## Abstract

Background: We previously established that striatal, but not cortical, dopaminergic activation stimulates movement, indicating that the crucial and original site of dopaminergic stimulation of motor function is the striatum, not the motor cortex. In the present study, we have further investigated the potential effects of the cortical and striatal dopaminergic activity on cortical pyramidal neuron physiology. Methods and Results: First, under a constant fluorescence imaging condition, we established that DA innervation and D1R and D2R expression were very low in the cerebral cortex but very high in the striatum. Second, we performed cellular neurophysiological experiments on layer 2/3 pyramidal neurons in the primary motor cortex (M1) in tyrosine hydroxylase gene knockout (TH-KO) DA-depleted mice that have hyperfunctional DA receptors. Using brain slice–whole-cell patch-clamping techniques, we found that M1 layer 2/3 pyramidal neurons had lower input resistance, stronger inward rectification, more negative RMP, and fired fewer spikes in DA-depleted TH-KO mice than in DA-intact WT mice; M1 layer 2/3 pyramidal neurons also had a diminished synaptic release function with reduced frequencies for spontaneous and miniature excitatory synaptic currents in TH-KO mice compared to WT mice. Third, we also found that when TH-KO mice were treated with L-dopa before brain slice preparation, these neurophysiological deficits of M1 layer 2/3 pyramidal neurons were reversed, but 30 min incubation of cortical brain slices with 10–20 μM DA produced no detectable effect in M1 layer 2/3 pyramidal neurons in TH-KO mice and WT mice. Fourth, Golgi staining showed that cortical pyramidal neuron morphology was indistinguishable between WT mice and TH-KO mice. Conclusions: Our results indicate that DA loss in the striatum, not in the cortex, indirectly reduces cortical pyramidal neuron membrane excitability and weakens synaptic function. Our data also indicate that (1) the normal direct effects of the cortical DA system on cortical pyramidal neurons are weak, (2) the striatal DA system is the dominant DA system in the brain, and (3) striatal DA activity can indirectly increase cortical neuron activity (spike firing and synaptic activity) and thus critically contribute to brain function. Additionally, our data suggest that in DA depletion rodent PD models, DA loss-induced effects on cortical pyramidal neurons and other neurons are functional rather than structural, such that DA replenishment restores motor function almost instantaneously. These findings provide important insights into how the brain’s dopaminergic system controls our motor and cognitive functions and indicate that the striatum is the main therapeutic target of dopaminergic drugs.